Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Mar 06, 2019 11:04am
111 Views
Post# 29449419

RE:CROI Video/Slides on NASH & HIV

RE:CROI Video/Slides on NASH & HIV
Nice find.

We had grand rounds on NASH yesterday. The gist of it is there are no great therapies approved at this time. As docs, we almost don’t look for it because we can’t treat it other than treating risk factors.

I am very confident TH with present good NASH data in a few weeks and have a conference call to discuss results and steps forward.

This price is a gift.

bfw


Wino115 wrote: Good presentation from McGill Prof. that shows the increasing risk and prevalence of NASH in HIV community and the increase in deaths thereof.  Plenty of slides showing it.  Then she talks about treatments and shows a study from Spain that switching from one ART to a new one showed it helped (but only 37 patients and the Q&A talks more about it), but basically saying diet and Vitamin E.  More or less shows there's no real solution to this epidemic yet.  Would make you excited that if you had a meaningful reduction, you' d have a good market just in HIV marketplace.

On weight loss treatment, in Q&A a S.Afr doctor says most of his patients are lean, so weight loss is out of the question. In response, 1 in 4 are lean NASH, so need something more.

[url=https://www.croiwebcasts.org/console/player/41029?mediaType=slideVideo&]CROI HIV and NASH[/url]




Bullboard Posts